The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...

Funded by a $3 million National Institutes of Health grant, the two universities plan to study the relationship between two ...

According to recent research published in ‘Alzheimer's & Dementia’, delays in entering the rapid eye movement (REM) sleep ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Taking longer to drift into the dreaming phase – known as rapid eye movement (REM) sleep – could be an early sign of ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

According to the Alzheimer’s Association ( there are currently 6.5 million people with Alzheimer’s disease. An estimated 6.9 ...

Gavin Patterson joins Alzheimer's Research UK as chair. The former President and Chief Revenue Officer of Salesforce and CEO ...